Zurich, 21st of November 2024: Xlife Sciences AG (SIX: XLS) announces the planned listing of its portfolio company, FUSE-AI GmbH, on the main segment of the London Stock Exchange, following an unanimous resolution passed at the general shareholders' meeting on November 20, 2024. The listing is scheduled for the first half of 2025 and will be executed in collaboration with an experienced consortium and selected institutional investors.
FUSE-AI GmbH, a Hamburg-based company specializing in the development of AI-powered software solutions for the clinical sector, has established itself in recent years as an innovative player in the field of medical artificial intelligence and has obtained market approval. The planned listing represents a crucial step towards scaling FUSE-AI GmbH’s activities further and underscores the potential of AI-driven technologies to significantly improve efficiency and precision in healthcare delivery.
Oliver R. Baumann, CEO of Xlife Sciences AG, commented: «The planned listing of FUSE-AI GmbH on the London Stock Exchange is a significant milestone—both for the company itself and for Xlife Sciences AG’s strategy to foster innovative research and bring it to market maturity. With a strong network and strategic investors, FUSE-AI GmbH is well-positioned to establish itself as a global provider in the field of medical AI. Moreover, through the planned listing of FUSE-AI GmbH, Xlife Sciences AG is showcasing one of its preferred exit strategies.»
FUSE-AI GmbH has gained particular recognition with its AI software solution «Prostate.Carcinoma.ai», which enables radiologists to save over 30% of time in MRI image analysis and reduces the error rate significantly from an average of 14% to 1%. The software is already ready for distribution in more than 42 countries, with recurring revenues being generated through distributors. This technology forms the foundation for further growth and the expansion into new application areas in diagnostic assistance software. The planned listing is intended to support ambitious growth goals by adding new indications (e.g. breast, lung, and skin cancer) every 6-9 months using the established and Europe-approved AI backbone.
Financial calendar
| Annual Report 2024 |
25 April 2025 |
| Annual Shareholders Meeting 2025 |
24 June 2025 |
| Half-Year Report 2025 |
23 September 2025 |
